title: Pharmacokinetic profile of Optivate® (high-purity factor VIII/von Willebrand factor concentrate) in treating von Willebrand disease.
authors.affiliation: Bio Products Laboratory Limited (Ltd), Dagger Lane, Elstree, Hertfordshire, UK.
authors.forename: R
authors.initials: R
authors.lastname: Shaikh-Zaidi
authors.affiliation: Thrombosis and Hemostasis Unit, National Hemophilia Center, Sheba Medical Center, Tel-Hashomer, Tel-Aviv, Israel.|Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Lubetsky
authors.affiliation: Thrombosis and Hemostasis Unit, Rabin Medical Center and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Inbal
authors.affiliation: CD Consultants, St Albans, UK.
authors.forename: C
authors.initials: C
authors.lastname: Dash
mesh_terms: D000328:Adult; D000368:Aged; D019540:Area Under Curve; D004338:Drug Combinations; D005169:Factor VIII / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult; D014842:von Willebrand Diseases / Q000188:drug therapy* / Q000378:metabolism*; D014841:von Willebrand Factor / Q000493:pharmacokinetics* / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C568131:optivate; D014841:von Willebrand Factor; D005169:Factor VIII